PRRT genomic signature in blood for prediction of 177 Lu-octreotate efficacy

Volume: 45, Issue: 7, Pages: 1155 - 1169
Published: Feb 26, 2018
Abstract
Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ)...
Paper Details
Title
PRRT genomic signature in blood for prediction of 177 Lu-octreotate efficacy
Published Date
Feb 26, 2018
Volume
45
Issue
7
Pages
1155 - 1169
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.